Seeking synergy for novel weight- and glucose-lowering pharmacotherapy and exercise training in heart failure patients with preserved ejection fraction

Heart failure (HF) with preserved ejection fraction (HFpEF; EF > 50%) accounts for more than 50% of new HF diagnoses, and the prevalence is increasing due to the ageing population and the rising prevalence of obesity. 1,2Heart failure with preserved ejection fraction is associated with multisystem structural and functional abnormalities, contributing to a reduced physical functioning, exercise capacity, and quality of life (QoL), which subsequently increases the risk for sarcopenic obesity, frailty, unplanned hospitalizations, and mortality. 1,